The international guideline recommendations for low-density lipoprotein cholesterol (LDL-C) lowering were made based on the results of randomized controlled trials (RCTs), meta-analyses, and observational studies mostly in the White population. It was not clear whether these LDL-C targets could be applicable to other ethnic groups, for example, Asian patients. This review aimed to address major aspects related to the lipid goal and statin therapy in Asia, including the epidemiology of cardiovascular disease, the LDL-C profiles, the lipid goals from localized guidelines, genetics and lifestyles, and the efficacy and safety of statins. Owing to the geographic, ethnic, genetic, and cultural diversity in this region, we observed a geographic pattern of diversity in cardiovascular epidemiology and statin response in Central Asia, East Asia (particularly for Asia-Pacific region), and South Asia. The rapidly growing literature from Asian countries questioning “lower is better” hypothesis was noticed. However, owing to the nature of these dominantly observational data, the conclusion was hardly confirmative. Despite the rapid expansion of the current literature in this region, efforts should be made to ensure an adequate sample size to assess the significance of a given lipid parameter on overall cardiovascular outcomes in this Asian population.
SteinE. The lower the better? Reviewing the evidence for more aggressive cholesterol reduction and goal attainment. Atheroscler Suppl2002; 2: 19–25.
2.
CollinsRArmitageJParishS, et al.MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomized placebo-controlled trial. Lancet2002; 360: 7–7.
3.
National Cholesterol Education Program Expert Panel. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation2002; 106: 3143–3143.
4.
StoneNJRobinsonJGLichtensteinAH, et al.2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol2014; 63: 2889–2934.
5.
National Cholesterol Education Program Expert Panel. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation2002; 106: 3143–3143.
6.
GrundySMCleemanJIMerzCNB, et al.Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. J Am Coll Cardiol2004; 44: 720–732.
7.
CatapanoALGrahamIDe BackerG, et al.2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J2016; 37: 2999–3058.
8.
JellingerPSHandelsmanYRosenblitPD, et al.American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocrine Practice2017; 23: 1–87.
9.
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2018: 25709.
10.
RidkerPMGroupJS. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein rationale and design of the JUPITER trial. Circulation2003; 108: 2292–2297.
11.
RothGAHuffmanMDMoranAE, et al.Global and regional patterns in cardiovascular mortality from 1990 to 2013. Circulation2015; 132: 1667–1678.
Eastern Stroke Coronary Heart Disease Collaborative Research. Collaborative ESCHD. Blood pressure, cholesterol, and stroke in Eastern Asia. Lancet1998; 352: 1801–1807.
16.
RodgersALawesCMacMahonS. Reducing the global burden of blood pressure-related cardiovascular disease. J Hypertens Suppl2000; 18: S3–S6.
17.
Asia Pacific Cohort Studies Collaboration. CollaborationAPCS. Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens2003; 21: 707–716.
18.
ParkSBuranakitjaroenPChenC-H, et al.Expert panel consensus recommendations for home blood pressure monitoring in Asia: the Hope Asia Network. J Human Hypertens2018; 32: 249–258.
19.
GuerreroAE. 2015 Clinical Practice Guidelines for the Management of Dyslipidemia in the Philippines - Executive Summary: Dyslipidemia Guidelines 2015. ASEAN Heart J2016; 24: 7–7.
20.
Joint Committee for Guideline Revision. 2016 Chinese guidelines for the management of dyslipidemia in adults. J Geriatric Cardiol2018; 15: 1–29.
21.
ZhaoS-P. Amendment of the low-density lipoprotein cholesterol target in the ‘Chinese Guidelines for the Prevention and Treatment of Adult Dyslipidemia’: opinion. Chronic Diseases Translational Med2016; 2: 7–7.
22.
HuD-Y. New guidelines and evidence for prevention and treatment of dyslipidemia and atherosclerotic cardiovascular disease in China. Chronic Diseases Translational Med2017; 3: 73–73.
23.
WongMCSinCKLeeJP. The reference framework for diabetes care in primary care settings. Xianggang yi xue za zhi2012; 18: 238–246.
24.
LiYHUengKCJengJS, et al.2017 Taiwan lipid guidelines for high risk patients. Taiwan yi zhi2017; 116: 217–248.
25.
TeramotoTSasakiJIshibashiS, et al.Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan—2012 version. J Atheroscler Thrombosis2013; 20: 517–523.
26.
IyengarSPuriRNarasinganS. Lipid association of India expert consensus statement on management of dyslipidemia in Indians 2016 - part 1. J Practice Cardiovasc Sci2016; 2: 134–134.
27.
ChenYWangCShangH, et al.Clinical practice guidelines in China. BMJ2018; 360: j5158–j5158.
28.
SetiaSFungSS-WWatersDD. Doctors’ knowledge, attitudes, and compliance with 2013 ACC/AHA guidelines for prevention of atherosclerotic cardiovascular disease in Singapore. Vascular Health Risk Management2015; 11: 303–303.
29.
HuMTomlinsonB. Lipid-lowing pharmacogenomics in Chinese patients. Expert Rev Cardiovasc Ther2013; 11: 985–997.
30.
MaggoSDKennedyMAClarkDW. Clinical implications of pharmacogenetic variation on the effects of statins. Drug Safety2011; 34: 1–19.
31.
BrownFSingerAKatzA, et al.Statin-prescribing trends for primary and secondary prevention of cardiovascular disease. Can Family Physician2017; 63: e495–e503.
32.
GolombBAEvansMA. Statin adverse effects. Am J Cardiovasc Drugs2008; 8: 373–418.
33.
ChanJCKongAPBaoW, et al.Safety of atorvastatin in Asian patients within clinical trials. Cardiovasc Therapeut2016; 34: 431–440.
34.
YeY-CZhaoX-LZhangS-Y. Use of atorvastatin in lipid disorders and cardiovascular disease in Chinese patients. Chin Med J2015; 128: 259–259.
35.
LiDQKimRBMcArthurE, et al.Statin safety in Chinese: a population-based study of older adults. PLoS ONE2016; 11: e0150990–e0150990.
36.
ZhuJRTomlinsonBRoYM, et al.A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study). Curr Med Res Opin2007; 23: 3055–3068. 2008/01/16.
37.
LiuPJiangJLiJ, et al.Intensive statin therapy for Chinese patients with coronary artery disease undergoing percutaneous coronary intervention (ISCAP study). Catheteriz Cardiovasc Intervent2012; 79: 967–971.
38.
ZhaoSPYuBLPengDQ, et al.The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: Results of the CHILLAS trial. Atherosclerosis2014; 233: 707–712.
39.
UeshimaKItohHKanazawaN, et al.Rationale and design of the standard versus intensive statin therapy for hypercholesterolemic patients with diabetic retinopathy (EMPATHY) study: a randomized controlled trial. J Atheroscler Thrombosis2016; 23: 976–990.
40.
LeeERyanSBirminghamB, et al.Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Therapeut2005; 78: 330–341.
41.
GuptaMBragaMFTeohH, et al.Statin effects on LDL and HDL cholesterol in South Asian and white populations. J Clin Pharmacol2009; 49: 831–837.
42.
DeedwaniaPCGuptaMSteinM, et al.Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial). Am J Cardiol2007; 99: 1538–1543.
43.
LiaoJK. Safety and efficacy of statins in Asians. Am J Cardiol2007; 99: 410–414.
44.
MenonASKotwalNSinghY, et al.Statins: Cholesterol guidelines and Indian perspective. Indian J Endocrinol Metabol2015; 19: 546–546.
45.
RengesHWileDMcKeigueP, et al.Apolipoprotein B gene polymorphisms are associated with lipid levels in men of South Asian descent. Atherosclerosis1991; 91: 267–275.
46.
ShethTNairCNargundkarM, et al.Cardiovascular and cancer mortality among Canadians of European, south Asian and Chinese origin from 1979 to 1993 an analysis of 1.2 million deaths. Can Med Assoc J1999; 161: 132–138.
47.
RashidSSnidermanAMeloneM, et al.Elevated cholesteryl ester transfer protein (CETP) activity, a major determinant of the atherogenic dyslipidemia, and atherosclerotic cardiovascular disease in South Asians. Eur J Prevent Cardiol2015; 22: 468–477.
48.
MisraAShrivastavaU. Obesity and dyslipidemia in South Asians. Nutrients2013; 5: 2708–2733.
49.
AhmedEEl-MenyarA. South Asian ethnicity and cardiovascular risk: the known, the unknown, and the paradox. Angiology2015; 66: 405–415.
50.
EnasEA. Why is there an epidemic of malignant CAD in young Indians. Asian J Clin Cardiol1998; 1: 43–59.
51.
EnasEGargADavidsonM, et al.Coronary heart disease and its risk factors in first-generation immigrant Asian Indians to the United States of America. Indian Heart J1996; 48: 343–353.
52.
EnasEADhawanJPetkarS. Coronary artery disease in Asian Indians: lessons learnt and the role of lipoprotein (a). Indian Heart J1997; 49: 25–34.
53.
NagTGhoshA. Cardiovascular disease risk factors in Asian Indian population: a systematic review. J Cardiovasc Disease Res2013; 4: 222–228.
54.
KamathSKHussainEAAminD, et al.Cardiovascular disease risk factors in 2 distinct ethnic groups: Indian and Pakistani compared with American premenopausal women. Am J Clin Nutr1999; 69: 621–631.
55.
MohanVSandeepSDeepaR, et al.Epidemiology of type 2 diabetes: Indian scenario. Indian J Med Res2007; 125: 217–230.
56.
GuptaSGudapatiRGauravK, et al.Emerging risk factors for cardiovascular diseases: Indian context. Indian J Endocrinol Metabol2013; 17: 806–806.
57.
van AbeelenAFEliasSGBossuytPM, et al.Cardiovascular consequences of famine in the young. Eur Heart J2011; 33: 538–545.
58.
LeeCWKangS-JAhnJ-M, et al.Comparison of effects of atorvastatin (20 mg) versus rosuvastatin (10 mg) therapy on mild coronary atherosclerotic plaques (from the ARTMAP trial). Am J Cardiol2012; 109: 1700–1704.
59.
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial. Lancet2002; 360: 7–22.
60.
MatsuzakiMKitaTMabuchiH, et al.Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia. Circulat J2002; 66: 1087–1095.
61.
LiaoJK. Safety and efficacy of statins in Asians. Am J Cardiol2007; 99: 410–414.
62.
MiyauchiKRayK. A review of statin use in patients with acute coronary syndrome in Western and Japanese populations. J Int Med Res2013; 41: 523–536.
63.
WangP. Statin dose in Asians: is pharmacogenetics relevant?Pharmacogenomics2011; 12: 1605–1615.
64.
NaitoRMiyauchiKDaidaH. Racial differences in the cholesterol-lowering effect of statin. J Atheroscler Thrombosis2017; 24: 19–25.
65.
TomlinsonBChanPLiuZ-M. Statin responses in Chinese patients. J Atheroscler Thrombosis2017, pp. 40204–40204.
66.
HoangKCLeTVWongND. The metabolic syndrome in East Asians. J Cardiometabolic Syndrome2007; 2: 276–282.
67.
HeJKlagMJWuZ, et al.Effect of migration and related environmental changes on serum lipid levels in southwestern Chinese men. Am J Epidemiol1996; 144: 839–848.
68.
TaiESTanCE. Genes, diet and serum lipid concentrations: lessons from ethnically diverse populations and their relevance to coronary heart disease in Asia. Curr Opin Lipidol2004; 15: 5–12.
69.
KengneAPNakamuraKBarziF, et al.Smoking, diabetes and cardiovascular diseases in men in the Asia Pacific region. J Diabetes2009; 1: 173–181.
70.
YangWXiaoJYangZ, et al.Serum lipids and lipoproteins in Chinese men and women. Circulation2012; 125: 2212–2221.
71.
EgusaGYamaneK. Lifestyle, serum lipids and coronary artery disease: comparison of Japan with the United States. J Atheroscler Thrombosis2004; 11: 304–312.
72.
EgusaGWatanabeHOhshitaK, et al.Influence of the extent of westernization of lifestyle on the progression of preclinical atherosclerosis in Japanese subjects. J Atheroscler Thrombosis2002; 9: 299–304.
73.
MarmotMSymeSLKaganA, et al.Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California: prevalence of coronary and hypertensive heart disease and associated risk factors. Am J Epidemiol1975; 102: 514–525.
74.
EnasEAChackoVPazhoorSG, et al.Dyslipidemia in south Asian patients. Curr Atheroscler Rep2007; 9: 367–374.
75.
ZhangJWangZWangH, et al.Association between dietary patterns and blood lipid profiles among Chinese women. Public Health Nutrition2016; 19: 3361–3368.
76.
HuMThomasGNTomlinsonB. Lipid disorders in Chinese populations. Clin Lipidol2011; 6: 549–562.
77.
LinC-FChangY-HChienS-C, et al.Epidemiology of dyslipidemia in the Asia pacific region. Int J Gerontol2018. in press.
78.
LesserIAGasevicDLearSA. The association between acculturation and dietary patterns of South Asian immigrants. PLoS ONE2014; 9: e88495–e88495.
79.
KhanSAJacksonRTMomenB. The relationship between diet quality and acculturation of immigrated South Asian American adults and their association with metabolic syndrome. PLoS ONE2016; 11: e0156851–e0156851.
80.
EnasEA. High rates of CAD in Asian Indians in the United States despite intense modification of lifestyle: what next?Curr Sci1998, pp. 1081–1086.
81.
SinghRBNiazMAGhoshS, et al.Low fat intake and coronary artery disease in a population with higher prevalence of coronary artery disease: the Indian paradox. J Am Coll Nutrition1998; 17: 342–350.
82.
ArdeshnaDRBob-ManuelTNandaA, et al.Asian-Indians: a review of coronary artery disease in this understudied cohort in the United States. Ann Translational Med2018; 6: 12–12.
83.
HamazakiTOkuyamaHOgushiY, et al.Towards a paradigm shift in cholesterol treatment. Ann Nutr Metab2015; 66: 1–116.
84.
NodaHIsoHIrieF, et al.Low-density lipoprotein cholesterol concentrations and death due to intraparenchymal hemorrhage: the Ibaraki Prefectural Health Study. Circulation2009; 119: 2136–2145.
85.
AhnTSuhSYLeeK, et al.Clinical Outcomes according to the Achievement of Target Low Density Lipoprotein-Cholesterol in Patients with Acute Myocardial Infarction. Korean Circulation J2017; 47: 31–35.
86.
ChoKHJeongMHParkKW, et al.Comparison of the effects of two low-density lipoprotein cholesterol goals for secondary prevention after acute myocardial infarction in real-world practice:≥ 50% reduction from baseline versus< 70mg/dL. Int J Cardiol2015; 187: 478–485.
87.
NatsuakiMFurukawaYMorimotoT, et al.Intensity of statin therapy, achieved low-density lipoprotein cholesterol levels and cardiovascular outcomes in Japanese patients after coronary revascularization. Circulation J2012; 76: 1369–1379.
88.
LeeVWChauRYCheungHY, et al.How low should we target the LDL goal to improve survival for acute coronary syndrome patients in Hong Kong?BMC Cardiovasc Disord2015; 15: 117–117.
89.
WangYYanBPNicholMB, et al.Real-world study of low-density lipoprotein cholesterol levels and cardiovascular outcomes in Chinese: A retrospective cohort study in post-percutaneous coronary intervention acute coronary syndrome patients. Int J Cardiol2017; 249: 18–24.
90.
BilenOKamalAViraniSS. Lipoprotein abnormalities in South Asians and its association with cardiovascular disease: Current state and future directions. World J Cardiol2016; 8: 247–247.
91.
SinghVDeedwaniaP. Dyslipidemia in special populations: Asian Indians, African Americans, and Hispanics. Curr Atheroscler Rep2006; 8: 32–40.
92.
Asia Pacific Cohort Studies Collaboration. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int J Epidemiol2003; 32: 563–572.
93.
PohK-KAmbegaonkarBBaxterCA, et al.Low-density lipoprotein cholesterol target attainment in patients with stable or acute coronary heart disease in the Asia-Pacific region: results from the Dyslipidemia International Study II. Eur J Prevent Cardiol2018; 25: 1950–1963.
94.
FerrieresJDe FerrariGMHermansMP, et al.Predictors of LDL-cholesterol target value attainment differ in acute and chronic coronary heart disease patients: Results from DYSIS II Europe. Eur J Prev Cardiol2018; 25: 1966–1976.
95.
NguyenHNFujiyoshiAAbbottRD, et al.Epidemiology of cardiovascular risk factors in Asian countries. Circulation J2013; 77: 2851–2859.
96.
World Health Organization. Accelerating collaboration: regional consultation of WHO collaborating centres in South-East Asia Region, New Delhi, India 19–21 October 2016. 2017.
97.
RahmanMSekimotoMMorimotoT, et al.Randomized controlled trials conducted in Japan as a comparison with top-ranking countries. J Epidemiol2001; 11: 46–47.
98.
KipKEHollabaughKMarroquinOC, et al.The problem with composite end points in cardiovascular studies: the story of major adverse cardiac events and percutaneous coronary intervention. J Am Coll Cardiol2008; 51: 701–707.
99.
OrdingAGCronin-FentonDEhrensteinV, et al.Challenges in translating endpoints from trials to observational cohort studies in oncology. Clin Epidemiol2016; 8: 195–195.
100.
GoldbergRGoreJMBartonB, et al.Individual and composite study endpoints: separating the wheat from the chaff. Am J Med2014; 127: 379–384.
Chinese Joint Committee for Guideline Revision. 2016 Chinese guidelines for the management of dyslipidemia in adults. J Geriatric Cardiol2018; 15: 1–29.
103.
Department of Health Hong Kong Government. HK Reference Framework for Diabetes Care for Adults in Primary Care Settings. Department of Health, Hong Kong, 2017.
LiYHUengKCJengJS, et al.2017 Taiwan lipid guidelines for high risk patients. Taiwan yi zhi2017; 116: 217–248.
106.
LeeJ-HKoY-GShinD-H, et al.Attainment of low-density lipoprotein cholesterol goal after endovascular treatment is associated with reduced cardiovascular events in patients with peripheral arterial disease. J Vasc Surg2016; 63: 756–763.
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
